Manning & Napier Life Sciences
290 Woodcliff Drive Fairport, NY 14450
Map
Phone: 800-466-3863
| Category: | Specialty-Health | | Fund Family: | Manning & Napier | | Net Assets: | 281.24M | | Year-to-Date Return: | -7.54% | | Yield: | 0.00% | | Morningstar Rating: |  | | Fund Inception Date: | 05-Nov-99 |
|
Jeffrey Coons
Lead Manager since
05-Nov-99 | | | Coons is a senior analyst. He joined the Advisor in 1993. Coons has been a co-director of research since 2002. Previously, he served as a managing director with Manning & Napier Advisors, Inc. from 1993 to 2002.He Business Experience During Last Five Years. Coons holds the Chartered Financial Analyst designation. |
| Min Initial Investment: | $2,000 | | Min Initial Investment, IRA: | $0 | | Min Initial Investment, AIP: | $2,000 | | Min Subsequent Investment: | $0 | | Min Subsequent Investment, IRA: | $0 | | Min Subsequent Investment, AIP: | $25 |
|
| |
| The investment seeks long-term growth. The fund invests at least 80% of assets in securities of companies involved in the life sciences industry. It may invest in U.S. and foreign stocks, including American Depository Receipts (ADRs) and other U.S. dollar denominated securities of foreign issuers. The fund is nondiversified. |
| Last Dividend
(16-Sep-02):
| 0.00 | | Last Cap Gain
(15-Sep-08):
| 0.11 | | Annual Holdings Turnover
| 95.00% | | Average for Category:
| 101.64% |
|
| Expense | EXLSX | Category
Avg | | Total Expense Ratio: | 1.12%
| 1.67% | | Max 12b1 Fee: | 0.00%
| N/A | | Max Front End Sales Load: | 0.00%
| 5.30% | | Max Deferred Sales Load: | 0.00%
| 2.94% | | 3 Yr Expense Projection*: |
$356 | $722 | | 5 Yr Expense Projection*: |
$617 | $1,074 | | 10 Yr Expense Projection*: |
$1,363 | $2,092 |
|
|
5.38% Nasdaq 
0.19 (2.57%) 
Profile
